Details der Publikation - Other malignancies in the history of CLL

Other malignancies in the history of CLL : an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

© 2023 Published by Elsevier Ltd..

Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work.

Methods: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022.

Findings: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79-4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49-2.11; p < 0.001/OR = 1.89; 95% CI = 1.6-2.24; p < 0.001).CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36-2.41; p < 0.001/OR = 2.11; 95% CI = 1.12-3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08-0.33; p < 0.001).Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001).

Interpretation: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.

Funding: AbbVie, and EU/EFPIAInnovative Medicines Initiative Joint Undertaking HARMONY grant n° 116026.

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:65
Enthalten in:	EClinicalMedicine - 65(2023) vom: 28. Nov., Seite 102307

Sprache:	Englisch

Beteiligte Personen:	Chatzikonstantinou, Thomas [VerfasserIn] Scarfò, Lydia [VerfasserIn] Karakatsoulis, Georgios [VerfasserIn] Minga, Eva [VerfasserIn] Chamou, Dimitra [VerfasserIn] Iacoboni, Gloria [VerfasserIn] Kotaskova, Jana [VerfasserIn] Demosthenous, Christos [VerfasserIn] Smolej, Lukas [VerfasserIn] Mulligan, Stephen [VerfasserIn] Alcoceba, Miguel [VerfasserIn] Al-Shemari, Salem [VerfasserIn] Aurran-Schleinitz, Thérèse [VerfasserIn] Bacchiarri, Francesca [VerfasserIn] Bellido, Mar [VerfasserIn] Bijou, Fontanet [VerfasserIn] Calleja, Anne [VerfasserIn] Medina, Angeles [VerfasserIn] Khan, Mehreen Ali [VerfasserIn] Cassin, Ramona [VerfasserIn] Chatzileontiadou, Sofia [VerfasserIn] Collado, Rosa [VerfasserIn] Christian, Amy [VerfasserIn] Davis, Zadie [VerfasserIn] Dimou, Maria [VerfasserIn] Donaldson, David [VerfasserIn] Santos, Gimena Dos [VerfasserIn] Dreta, Barbara [VerfasserIn] Efstathopoulou, Maria [VerfasserIn] El-Ashwah, Shaimaa [VerfasserIn] Enrico, Alicia [VerfasserIn] Fresa, Alberto [VerfasserIn] Galimberti, Sara [VerfasserIn] Galitzia, Andrea [VerfasserIn] García-Serra, Rocío [VerfasserIn] Gimeno, Eva [VerfasserIn] González-Gascón-Y-Marín, Isabel [VerfasserIn] Gozzetti, Alessandro [VerfasserIn] Guarente, Valerio [VerfasserIn] Guieze, Romain [VerfasserIn] Gogia, Ajay [VerfasserIn] Gupta, Ritu [VerfasserIn] Harrop, Sean [VerfasserIn] Hatzimichael, Eleftheria [VerfasserIn] Herishanu, Yair [VerfasserIn] Hernández-Rivas, José-Ángel [VerfasserIn] Inchiappa, Luca [VerfasserIn] Jaksic, Ozren [VerfasserIn] Janssen, Susanne [VerfasserIn] Kalicińska, Elżbieta [VerfasserIn] Laribi, Kamel [VerfasserIn] Karakus, Volkan [VerfasserIn] Kater, Arnon P [VerfasserIn] Kho, Bonnie [VerfasserIn] Kislova, Maria [VerfasserIn] Konstantinou, Eliana [VerfasserIn] Koren-Michowitz, Maya [VerfasserIn] Kotsianidis, Ioannis [VerfasserIn] Kreitman, Robert J [VerfasserIn] Labrador, Jorge [VerfasserIn] Lad, Deepesh [VerfasserIn] Levin, Mark-David [VerfasserIn] Levy, Ilana [VerfasserIn] Longval, Thomas [VerfasserIn] Lopez-Garcia, Alberto [VerfasserIn] Marquet, Juan [VerfasserIn] Martin-Rodríguez, Lucia [VerfasserIn] Maynadié, Marc [VerfasserIn] Maslejova, Stanislava [VerfasserIn] Mayor-Bastida, Carlota [VerfasserIn] Mihaljevic, Biljana [VerfasserIn] Milosevic, Ivana [VerfasserIn] Miras, Fatima [VerfasserIn] Moia, Riccardo [VerfasserIn] Morawska, Marta [VerfasserIn] Murru, Roberta [VerfasserIn] Nath, Uttam Kumar [VerfasserIn] Navarro-Bailón, Almudena [VerfasserIn] Oliveira, Ana C [VerfasserIn] Olivieri, Jacopo [VerfasserIn] Oscier, David [VerfasserIn] Panovska-Stavridis, Irina [VerfasserIn] Papaioannou, Maria [VerfasserIn] Papajík, Tomas [VerfasserIn] Kubova, Zuzana [VerfasserIn] Phumphukhieo, Punyarat [VerfasserIn] Pierie, Cheyenne [VerfasserIn] Puiggros, Anna [VerfasserIn] Rani, Lata [VerfasserIn] Reda, Gianluigi [VerfasserIn] Rigolin, Gian Matteo [VerfasserIn] Ruchlemer, Rosa [VerfasserIn] Daniel de Deus Santos, Marcos [VerfasserIn] Schipani, Mattia [VerfasserIn] Schiwitza, Annett [VerfasserIn] Shen, Yandong [VerfasserIn] Simkovic, Martin [VerfasserIn] Smirnova, Svetlana [VerfasserIn] Abdelrahman Soliman, Dina Sameh [VerfasserIn] Spacek, Martin [VerfasserIn] et al [Sonstige Person]

Links:	Volltext

Themen:	Chronic lymphocytic leukemia Journal Article Other cancers Other malignancies Second primary malignancies

Anmerkungen:	Date Revised 28.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE

doi:	10.1016/j.eclinm.2023.102307

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM365246328

Internformat


LEADER	01000caa a22002652 4500
001	NLM365246328
003	DE-627
005	20240329000221.0
007	cr uuu---uuuuu
008	231226s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.eclinm.2023.102307 \|2 doi
028	5	2	\|a pubmed24n1353.xml
035			\|a (DE-627)NLM365246328
035			\|a (NLM)38033506
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Chatzikonstantinou, Thomas \|e verfasserin \|4 aut
245	1	0	\|a Other malignancies in the history of CLL \|b an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a ƒaComputermedien \|b c \|2 rdamedia
338			\|a ƒa Online-Ressource \|b cr \|2 rdacarrier
500			\|a Date Revised 28.03.2024
500			\|a published: Electronic-eCollection
500			\|a Citation Status PubMed-not-MEDLINE
520			\|a © 2023 Published by Elsevier Ltd.
520			\|a Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work
520			\|a Methods: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022
520			\|a Findings: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79-4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49-2.11; p < 0.001/OR = 1.89; 95% CI = 1.6-2.24; p < 0.001).CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36-2.41; p < 0.001/OR = 2.11; 95% CI = 1.12-3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08-0.33; p < 0.001).Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001)
520			\|a Interpretation: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS
520			\|a Funding: AbbVie, and EU/EFPIAInnovative Medicines Initiative Joint Undertaking HARMONY grant n° 116026
650		4	\|a Journal Article
650		4	\|a Chronic lymphocytic leukemia
650		4	\|a Other cancers
650		4	\|a Other malignancies
650		4	\|a Second primary malignancies
700	1		\|a Scarfò, Lydia \|e verfasserin \|4 aut
700	1		\|a Karakatsoulis, Georgios \|e verfasserin \|4 aut
700	1		\|a Minga, Eva \|e verfasserin \|4 aut
700	1		\|a Chamou, Dimitra \|e verfasserin \|4 aut
700	1		\|a Iacoboni, Gloria \|e verfasserin \|4 aut
700	1		\|a Kotaskova, Jana \|e verfasserin \|4 aut
700	1		\|a Demosthenous, Christos \|e verfasserin \|4 aut
700	1		\|a Smolej, Lukas \|e verfasserin \|4 aut
700	1		\|a Mulligan, Stephen \|e verfasserin \|4 aut
700	1		\|a Alcoceba, Miguel \|e verfasserin \|4 aut
700	1		\|a Al-Shemari, Salem \|e verfasserin \|4 aut
700	1		\|a Aurran-Schleinitz, Thérèse \|e verfasserin \|4 aut
700	1		\|a Bacchiarri, Francesca \|e verfasserin \|4 aut
700	1		\|a Bellido, Mar \|e verfasserin \|4 aut
700	1		\|a Bijou, Fontanet \|e verfasserin \|4 aut
700	1		\|a Calleja, Anne \|e verfasserin \|4 aut
700	1		\|a Medina, Angeles \|e verfasserin \|4 aut
700	1		\|a Khan, Mehreen Ali \|e verfasserin \|4 aut
700	1		\|a Cassin, Ramona \|e verfasserin \|4 aut
700	1		\|a Chatzileontiadou, Sofia \|e verfasserin \|4 aut
700	1		\|a Collado, Rosa \|e verfasserin \|4 aut
700	1		\|a Christian, Amy \|e verfasserin \|4 aut
700	1		\|a Davis, Zadie \|e verfasserin \|4 aut
700	1		\|a Dimou, Maria \|e verfasserin \|4 aut
700	1		\|a Donaldson, David \|e verfasserin \|4 aut
700	1		\|a Santos, Gimena Dos \|e verfasserin \|4 aut
700	1		\|a Dreta, Barbara \|e verfasserin \|4 aut
700	1		\|a Efstathopoulou, Maria \|e verfasserin \|4 aut
700	1		\|a El-Ashwah, Shaimaa \|e verfasserin \|4 aut
700	1		\|a Enrico, Alicia \|e verfasserin \|4 aut
700	1		\|a Fresa, Alberto \|e verfasserin \|4 aut
700	1		\|a Galimberti, Sara \|e verfasserin \|4 aut
700	1		\|a Galitzia, Andrea \|e verfasserin \|4 aut
700	1		\|a García-Serra, Rocío \|e verfasserin \|4 aut
700	1		\|a Gimeno, Eva \|e verfasserin \|4 aut
700	1		\|a González-Gascón-Y-Marín, Isabel \|e verfasserin \|4 aut
700	1		\|a Gozzetti, Alessandro \|e verfasserin \|4 aut
700	1		\|a Guarente, Valerio \|e verfasserin \|4 aut
700	1		\|a Guieze, Romain \|e verfasserin \|4 aut
700	1		\|a Gogia, Ajay \|e verfasserin \|4 aut
700	1		\|a Gupta, Ritu \|e verfasserin \|4 aut
700	1		\|a Harrop, Sean \|e verfasserin \|4 aut
700	1		\|a Hatzimichael, Eleftheria \|e verfasserin \|4 aut
700	1		\|a Herishanu, Yair \|e verfasserin \|4 aut
700	1		\|a Hernández-Rivas, José-Ángel \|e verfasserin \|4 aut
700	1		\|a Inchiappa, Luca \|e verfasserin \|4 aut
700	1		\|a Jaksic, Ozren \|e verfasserin \|4 aut
700	1		\|a Janssen, Susanne \|e verfasserin \|4 aut
700	1		\|a Kalicińska, Elżbieta \|e verfasserin \|4 aut
700	1		\|a Laribi, Kamel \|e verfasserin \|4 aut
700	1		\|a Karakus, Volkan \|e verfasserin \|4 aut
700	1		\|a Kater, Arnon P \|e verfasserin \|4 aut
700	1		\|a Kho, Bonnie \|e verfasserin \|4 aut
700	1		\|a Kislova, Maria \|e verfasserin \|4 aut
700	1		\|a Konstantinou, Eliana \|e verfasserin \|4 aut
700	1		\|a Koren-Michowitz, Maya \|e verfasserin \|4 aut
700	1		\|a Kotsianidis, Ioannis \|e verfasserin \|4 aut
700	1		\|a Kreitman, Robert J \|e verfasserin \|4 aut
700	1		\|a Labrador, Jorge \|e verfasserin \|4 aut
700	1		\|a Lad, Deepesh \|e verfasserin \|4 aut
700	1		\|a Levin, Mark-David \|e verfasserin \|4 aut
700	1		\|a Levy, Ilana \|e verfasserin \|4 aut
700	1		\|a Longval, Thomas \|e verfasserin \|4 aut
700	1		\|a Lopez-Garcia, Alberto \|e verfasserin \|4 aut
700	1		\|a Marquet, Juan \|e verfasserin \|4 aut
700	1		\|a Martin-Rodríguez, Lucia \|e verfasserin \|4 aut
700	1		\|a Maynadié, Marc \|e verfasserin \|4 aut
700	1		\|a Maslejova, Stanislava \|e verfasserin \|4 aut
700	1		\|a Mayor-Bastida, Carlota \|e verfasserin \|4 aut
700	1		\|a Mihaljevic, Biljana \|e verfasserin \|4 aut
700	1		\|a Milosevic, Ivana \|e verfasserin \|4 aut
700	1		\|a Miras, Fatima \|e verfasserin \|4 aut
700	1		\|a Moia, Riccardo \|e verfasserin \|4 aut
700	1		\|a Morawska, Marta \|e verfasserin \|4 aut
700	1		\|a Murru, Roberta \|e verfasserin \|4 aut
700	1		\|a Nath, Uttam Kumar \|e verfasserin \|4 aut
700	1		\|a Navarro-Bailón, Almudena \|e verfasserin \|4 aut
700	1		\|a Oliveira, Ana C \|e verfasserin \|4 aut
700	1		\|a Olivieri, Jacopo \|e verfasserin \|4 aut
700	1		\|a Oscier, David \|e verfasserin \|4 aut
700	1		\|a Panovska-Stavridis, Irina \|e verfasserin \|4 aut
700	1		\|a Papaioannou, Maria \|e verfasserin \|4 aut
700	1		\|a Papajík, Tomas \|e verfasserin \|4 aut
700	1		\|a Kubova, Zuzana \|e verfasserin \|4 aut
700	1		\|a Phumphukhieo, Punyarat \|e verfasserin \|4 aut
700	1		\|a Pierie, Cheyenne \|e verfasserin \|4 aut
700	1		\|a Puiggros, Anna \|e verfasserin \|4 aut
700	1		\|a Rani, Lata \|e verfasserin \|4 aut
700	1		\|a Reda, Gianluigi \|e verfasserin \|4 aut
700	1		\|a Rigolin, Gian Matteo \|e verfasserin \|4 aut
700	1		\|a Ruchlemer, Rosa \|e verfasserin \|4 aut
700	1		\|a Daniel de Deus Santos, Marcos \|e verfasserin \|4 aut
700	1		\|a Schipani, Mattia \|e verfasserin \|4 aut
700	1		\|a Schiwitza, Annett \|e verfasserin \|4 aut
700	1		\|a Shen, Yandong \|e verfasserin \|4 aut
700	1		\|a Simkovic, Martin \|e verfasserin \|4 aut
700	1		\|a Smirnova, Svetlana \|e verfasserin \|4 aut
700	1		\|a Abdelrahman Soliman, Dina Sameh \|e verfasserin \|4 aut
700	1		\|a Spacek, Martin \|e verfasserin \|4 aut
700	0		\|a et al \|4 oth
773	0	8	\|i Enthalten in \|t EClinicalMedicine \|d 2018 \|g 65(2023) vom: 28. Nov., Seite 102307 \|w (DE-627)NLM289300495 \|x 2589-5370 \|7 nnns
773	1	8	\|g volume:65 \|g year:2023 \|g day:28 \|g month:11 \|g pages:102307
856	4	0	\|u http://dx.doi.org/10.1016/j.eclinm.2023.102307 \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a GBV_NLM
951			\|a AR
952			\|d 65 \|j 2023 \|b 28 \|c 11 \|h 102307

Other malignancies in the history of CLL : an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände